US0070021086 - Common Stock - After market: 8.96 0 (0%)
NASDAQ:ACET (1/27/2023, 7:00:00 PM)+0.07 (+0.79%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-08 2022-11-08/amc | Earnings (Next) | 03-13 2023-03-13 |
Ins Owners | 0.69% | Inst Owners | 96.08% |
Market Cap | 383.95M | Shares | 42.85M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 87.06 |
IPO | 01-26 2018-01-26 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2018-01-26. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL), to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its lead product candidate, ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is under Phase I study for the treatment of Non-Hodgkin's Lymphoma. Its pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15, for the treatment of solid tumors. In addition, it is engaged in discovery and preclinical stage activities of its pipeline of product candidates for both hematological malignancies and solid tumors.
ADICET BIO INC
200 Berkeley Street, 19Th Floor
Boston MASSACHUSETTS 02116
P: 16174822333.0
CEO: Chen Schor
Employees: 86
Website: https://www.adicetbio.com/
Adicet Bio (ACET) dropped ~38% on Monday after the company updated data from an ongoing Phase 1 trial for its experimental CAR T cell ADI-001 in blood cancer. Read full story here.
Here you can normally see the latest stock twits on ACET, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: